Insmed Inc. (INSM)
Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript
Insmed Incorporated (NASDAQ:INSM ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Bryan Dunn – Head of Investor Relations Will Lewis – Chair and Chief Executive Officer Sara Bonstein – Chief Financial Officer Martina Flammer – Chief Medical Officer Conference Call Participants Joe Schwartz – Leerink Partners Jessica Fye – JPMorgan Nicole Germino – Truist Securities Jason Zemansky – Bank of America Jennifer Kim – Cantor Jeff Hung – Morgan Stanley Leon Wang – Barclays Steve Willey – Stifel Graig Suvannavejh – Mizuho Operator Thank you for standing by. My name is Jeannie, and I will be your conference operator today.
Insmed (INSM) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $1.10 per share a year ago.
Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 12 Stocks are Ripe for a Short Squeeze
Subscribers to Chart of the Week received this commentary on Sunday, September 8.
Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach
Insmed Incorporated's Q2 2024 revenue grew by 17% year-over-year, reaching $90.3 million, driven by strong ARIKAYCE sales. The company is preparing for the U.S. launch of brensocatib in mid-2025, pending regulatory approval in Q4 2024. Insmed's R&D expenses were $146.7 million in Q2 2024, down from the previous year due to prior non-cash acquisition costs.
Insmed Stock Surges 168% in the Past Six Months: Here's Why
Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.
Insmed Incorporated (INSM) Q2 2024 Earnings Call Transcript
Insmed Incorporated (NASDAQ:INSM ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Bryan Dunn – Head-Investor Relations Will Lewis – Chair and Chief Executive Officer Sara Bonstein – Chief Financial Officer Martina Flammer – Chief Medical Officer Conference Call Participants Jessica Fye – JPMorgan Ritu Baral – TD Cowen Joseph Schwartz – Leerink Partners Cameron Bozdog – Bank of America Jennifer Kim – Cantor Fitzgerald Leon Wang – Barclays Vamil Divan – Guggenheim Securities Liisa Bayko – Evercore ISI Graig Suvannavejh – Mizuho Nicole Germino – Truist Securities Andrea Tan – Goldman Sachs Operator Thank you for standing by. My name is John, and I will be your conference operator for today.
Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View
Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.
Compared to Estimates, Insmed (INSM) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.94 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.78 per share a year ago.
